Erratum to: Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer (Oncol Lett, (2015), 10, (2299-2302), 10.3892/ol.2015.3625);Synthesis and positron emission tomography evaluation of 18 F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2299-2302

  Fan, Weiwei ^a   Zhang, Zhiwei ^a   Zhu, Zheng ^a   Yang, Deyong ^a   Chen, Xiaochi ^a   Wang, Jianbo ^a   Chen, Feng ^a   Song, Xishuang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

2 3 1 Carboxy 5 (4 18 F fluoro benzoylamino) pentyl ureido pentanedioic acid; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

2 {3 [1 CARBOXY 5 (4 [18F] FLUORO BENZOYLAMINO) PENTYL] UREIDO} PENTANEDIOIC ACID; DIAGNOSTIC AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; HUMAN CELL; IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOCHEMISTRY; SYNTHESIS; TUMOR XENOGRAFT;

EID: 84940061757     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.4039     Document Type: Erratum

References (22)

1. Chen W, Mao K, Liu Z and Dinh-Xuan AT: The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review). Oncol Lett 8: 1907-1911, 2014 (Review).
2. Geus-Oei LF and Oyen WJ: Predictive and prognostic value of FDG-PET. Cancer Imaging 8: 70-80, 2008.
3. Liu Y: Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer. Oncol Lett 7: 2013-2018, 2014.
4. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS and Lin DW: Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 16: 5414-5423, 2010.
5. Chen XC, Yang DY and Che XY: Synthesis of PSMA-targeted small molecule Glu-urea-Lys analogue. J Dalian Med Univer 34: 13-17, 2012.
6. Silver DA, Pellicer I, Fair WR, Heston WD and Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-85, 1997.
7. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R and Gschwend JE: Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100: 786-793, 2007.
8. 18 F-fluoroacetate versus 11C-acetate. J Nucl Med 48: 420-428, 2007.
9. 18 F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 48: 46-55, 2007.
10. 18 F-fluoro-beta-D-arabinofuranosyl)thymine and PET. J Nucl Med 48: 1436-1441, 2007.
11. 18 F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45: 366-373, 2004.
12. Wang W and Mo ZN: Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue 16: 547-551, 2010 (In Chinese).
13. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH and Rajasekaran AK: A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 14: 4835-4845, 2003.
14. Kim H, Shoji S, Tomonaga T, Shima M, Terachi T and Uchida T: Prostate cancer with cyst formation detected by whole body positron emission tomography/computed tomography: A case report. Oncol Lett 8: 2037-2039, 2014.
15. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM and Bander NH: Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116 (Suppl): 1075-1083, 2010.
16. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC, et al: A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 52: 347-357, 2009.
17. Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF and Kozikowski AP: 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 1: 96-101, 2002.
18. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP and Pomper MG: Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11: 4022-4028, 2005.
19. 18 F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 14: 3036-3043, 2008.
20. Kularatne SA, Wang K, Santhapuram HK and Low PS: Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 6: 780-789, 2009.
21. Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, Lubkowski J and Spiegel DA: A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 132: 12711-12716, 2010.
22. Qi Y, Zhang Q, Huang Y and Wang D: Manifestations and pathological features of solitary thin-walled cavity lung cancer observed by CT and PET/CT imaging. Oncol Lett 8: 285-290, 2014.